Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257
Randi Y. Leavitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Grace A. McComsey(University Hospitals of Cleveland), Lumine H. Na(Brigham and Women's Hospital), Heather J. Ribaudo(Cancer Research And Biostatistics), Jeffrey L. Lennox(Emory University), Catherine Godfrey(United States Department of State), Manish Sagar(Evidence (Italy)), Raphael J. Landovitz(APLA Health), Susan E. Cohn(Brigham and Women's Hospital), Daniel R. Kuritzkes(Brigham and Women's Hospital), Bryan Baugh(Brigham and Women's Hospital), Francesca Aweeka(University of California, San Francisco), Todd T. Brown(Johns Hopkins University), Ighovwerha Ofotokun(Emory University), Judith S. Currier(University of California, Los Angeles), Michael F. Para(The Ohio State University), Kristine B. Patterson(University of North Carolina at Chapel Hill), Angelina Villası́s-Keever(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891